Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.
Chen G, Chen X, Zhang Y, Yan F, Fang W, Yang Y, Hong S, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Zhou N, Zhao H, Zhang L. Chen G, et al. Among authors: huang x, huang y. Cancer Med. 2017 May;6(5):953-961. doi: 10.1002/cam4.1059. Epub 2017 Apr 4. Cancer Med. 2017. PMID: 28374971 Free PMC article.
The comparison of EGFR-TKI failure modes and subsequent management between exon 19 deletion and exon 21 L858R mutation in advanced non-small-cell lung cancer.
Zhang Y, Chen G, Chen X, Fang W, Gao F, Yang Y, Zhao Y, Ma Y, Hong S, Zhang Z, Miao S, Wu M, Huang X, Luo Y, Zhou C, Gong R, Huang Y, Chen L, Zhou N, Zhao H, Zhang L. Zhang Y, et al. Among authors: huang x, huang y. J Cancer. 2017 Jul 2;8(10):1865-1871. doi: 10.7150/jca.19867. eCollection 2017. J Cancer. 2017. PMID: 28819384 Free PMC article.
The efficacy and toxicity of afatinib in advanced EGFR-positive non-small-cell lung cancer patients after failure of first-generation tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang Y, Miao S, Wang F, Fang W, Chen G, Chen X, Yan F, Huang X, Wu M, Huang Y, Zhang L. Zhang Y, et al. Among authors: huang x, huang y. J Thorac Dis. 2017 Jul;9(7):1980-1987. doi: 10.21037/jtd.2017.06.08. J Thorac Dis. 2017. PMID: 28839997 Free PMC article.
Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y, Chen C, Zhang X, Fu S, Xue C, Ma Y, Fang W, Yang Y, Hou X, Huang Y, Zhao H, Hong S, Zhang L. Zhou Y, et al. Among authors: huang y. J Immunother Cancer. 2018 Dec 22;6(1):155. doi: 10.1186/s40425-018-0477-9. J Immunother Cancer. 2018. PMID: 30577837 Free PMC article.
Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X, Zhao S, Zheng Q, Pan H, Zhang L, Long H, Yang H, Wang X, Wen Z, Wang J, Yang H, Xia X, Zhao Y, Hou X, Ma Y, Zhou T, Zhang Z, Zhan J, Huang Y, Zhao H, Zhou N, Yi X, Zhang L. Zhang Y, et al. Among authors: huang y. Mol Cancer. 2019 Jan 9;18(1):7. doi: 10.1186/s12943-019-0939-9. Mol Cancer. 2019. PMID: 30626401 Free PMC article.
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y, Chang L, Yang Y, Fang W, Guan Y, Wu A, Hong S, Zhou H, Chen G, Chen X, Zhao S, Zheng Q, Pan H, Zhang L, Long H, Yang H, Wang X, Wen Z, Wang J, Yang H, Xia X, Zhao Y, Hou X, Ma Y, Zhou T, Zhang Z, Zhan J, Huang Y, Zhao H, Zhou N, Yi X, Zhang L. Zhang Y, et al. Among authors: huang y. J Immunother Cancer. 2019 Apr 3;7(1):98. doi: 10.1186/s40425-019-0581-5. J Immunother Cancer. 2019. PMID: 30944026 Free PMC article.
75,549 results
You have reached the last available page of results. Please see the User Guide for more information.